An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease

被引:62
|
作者
Wilsey, Barth [1 ,2 ]
Marcotte, Thomas D. [3 ]
Deutsch, Reena [3 ]
Zhao, Holly [1 ,2 ]
Prasad, Hannah [1 ,2 ]
Phan, Amy [1 ,2 ]
机构
[1] Sacramento VA Med Ctr, VA Northern Calif Hlth Care Syst, Mather, CA USA
[2] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Lawrence J Ellison Ambulatory Care Ctr, Sacramento, CA USA
[3] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
基金
美国国家卫生研究院;
关键词
Neuropathic pain; analgesia; cannabis; clinical trial; neuropsychological testing; SERIAL-ADDITION TASK; MULTIPLE-SCLEROSIS; CLINICAL IMPORTANCE; SMOKED MARIJUANA; DOUBLE-BLIND; SUICIDAL BEHAVIORS; DRONABINOL; CROSSOVER; SYMPTOMS; EFFICACY;
D O I
10.1016/j.jpain.2016.05.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Using 8-hour human laboratory experiments, we evaluated the analgesic efficacy of vaporized cannabis in patients with neuropathic pain related to injury or disease of the spinal cord, most of whom were experiencing pain despite traditional treatment. After obtaining baseline data, 42 participants underwent a standardized procedure for inhaling 4 puffs of vaporized cannabis containing either placebo, 2.9%, or 6.7% delta 9-THC on 3 separate occasions. A second dosing occurred 3 hours later; participants chose to inhale 4 to 8 puffs. This flexible dosing was used to attempt to reduce the placebo effect. Using an 11-point numerical pain intensity rating scale as the primary outcome, a mixed effects linear regression model showed a significant analgesic response for vaporized cannabis. When subjective and psychoactive side effects (eg, good drug effect, feeling high, etc) were added as covariates to the model, the reduction in pain intensity remained significant above and beyond any effect of these measures (all P <.0004). Psychoactive and subjective effects were dose-dependent. Measurement of neuropsychological performance proved challenging because of various disabilities in the population studied. Because the 2 active doses did not significantly differ from each other in terms of analgesic potency, the lower dose appears to offer the best risk-benefit ratio in patients with neuropathic pain associated with injury or disease, of the spinal cord. Perspective: A crossover, randomized, placebo-controlled human laboratory experiment involving administration of vaporized cannabis was performed in patients with neuropathic pain related to spinal cord injury and disease. This study supports consideration of future research that would include longer duration studies over weeks to months to evaluate the efficacy of medicinal cannabis in patients with central neuropathic pain. (C) 2016 by the American Pain Society
引用
收藏
页码:982 / 1000
页数:19
相关论文
共 50 条
  • [31] Case report: The feasibility of rTMS with intrathecal baclofen pump for the treatment of unresolved neuropathic pain following spinal cord injury
    Foglia, Stevie D.
    Rehsi, Ravjot S.
    Turco, Claudia V.
    Shanthanna, Harsha
    Nelson, Aimee J.
    FRONTIERS IN REHABILITATION SCIENCES, 2022, 3
  • [32] Botulinum toxin type A treatment for persistent neuropathic pain in the soles after cervical spinal cord injury: A case report
    Mengi, Alper
    Turk, Bengi Gul
    Uygunoglu, Ugur
    TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, 2023, : 550 - 553
  • [33] The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study
    Hosseini, Marjan
    Karami, Zohreh
    Janzadenh, Atousa
    Jameie, Seyed Behnamedin
    Mashhadi, Zahra Haji
    Yousefifard, Mahmoud
    Nasirinezhad, Farinaz
    EMERGENCY, 2014, 2 (04): : 151 - 157
  • [34] Effect of coenzyme Q10 on neuropathic pain threshold resulting from spinal cord injury in male rats
    Hosseini, Marjan
    Karami, Zohreh
    Janzadeh, Atosa
    Nasirinezhad, Farinaz
    PHYSIOLOGY AND PHARMACOLOGY, 2014, 18 (02): : 204 - 214
  • [35] Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model
    Mahmoud Yousefifard
    Farinaz Nasirinezhad
    Homa Shardi Manaheji
    Atousa Janzadeh
    Mostafa Hosseini
    Mansoor Keshavarz
    Stem Cell Research & Therapy, 7
  • [36] Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model
    Yousefifard, Mahmoud
    Nasirinezhad, Farinaz
    Manaheji, Homa Shardi
    Janzadeh, Atousa
    Hosseini, Mostafa
    Keshavarz, Mansoor
    STEM CELL RESEARCH & THERAPY, 2016, 7
  • [37] High-frequency spinal cord stimulation treatment attenuates the increase in spinal glutamate release and spinal miniature excitatory postsynaptic currents in rats with spared nerve injury-induced neuropathic pain
    Liao, Wen-Tzu
    Tseng, Chia-Chih
    Chia, Wan-Ting
    Lin, Chung-Ren
    BRAIN RESEARCH BULLETIN, 2020, 164 : 307 - 313
  • [38] Novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury
    Liu, Wanhong
    Liu, Zhongchun
    Liu, Li
    Xiao, Zheman
    Cao, Xiongbin
    Cao, Zhijian
    Xue, Lu
    Miao, Lixia
    He, Xiaohua
    Li, Wenxin
    NEUROSCIENCE LETTERS, 2008, 432 (01) : 13 - 18
  • [39] Immersive interactive virtual walking reduces neuropathic pain in spinal cord injury: findings from a preliminary investigation of feasibility and clinical efficacy
    Trost, Zina
    Anam, Monima
    Seward, Joshua
    Shum, Corey
    Rumble, Deanna
    Sturgeon, John
    Mark, Victor
    Chen, Yuying
    Mitchell, Lucie
    Cowan, Rachel
    Perera, Robert
    Richardson, Elizabeth
    Richards, Scott
    Gustin, Sylvia
    PAIN, 2022, 163 (02) : 350 - 361
  • [40] Evaluation of a Clinical Protocol to Assess and Diagnose Neuropathic Pain During Acute Hospital Admission: Results From Traumatic Spinal Cord Injury
    Belanger, Lise M. A.
    Umedaly, Hamed S.
    Noonan, Vanessa K.
    Park, So Eyun
    Prince, Jennifer
    Thorogood, Nancy P.
    Shen, Tian
    Townson, Andrea F.
    Street, John T.
    Dvorak, Marcel F.
    Negraeff, Michael
    CLINICAL JOURNAL OF PAIN, 2018, 34 (02) : 104 - 112